FDA Draft guidance on Good ANDA Submission Practices [Regulatives / Guidelines]

posted by BRB  – Canada, 2018-01-03 22:42 (1908 d 19:50 ago) – Posting: # 18137
Views: 1,404

Hi all,

The FDA just posted a draft guidance on Good ANDA submission practices:


I found the section on deviations from product-specific guidances to be rather interesting such as:

A detailed justification for and data (such as their inclusion/exclusion criteria or demographic information) to support why their use of a particular study population does not affect their BE determination.

So for imatinib BE studies, which have been done in healthy subjects, but the guidance recommends to use patients, a detailed justification now needs to be provided?


Complete thread:

UA Flag
 Admin contact
22,552 posts in 4,724 threads, 1,606 registered users;
15 visitors (0 registered, 15 guests [including 6 identified bots]).
Forum time: 19:33 CEST (Europe/Vienna)

Learning of many things
does not teach intelligence.    Heraclitus of Ephesus

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz